MX2018004041A - Tratamiento de trastornos de acidos biliares. - Google Patents
Tratamiento de trastornos de acidos biliares.Info
- Publication number
- MX2018004041A MX2018004041A MX2018004041A MX2018004041A MX2018004041A MX 2018004041 A MX2018004041 A MX 2018004041A MX 2018004041 A MX2018004041 A MX 2018004041A MX 2018004041 A MX2018004041 A MX 2018004041A MX 2018004041 A MX2018004041 A MX 2018004041A
- Authority
- MX
- Mexico
- Prior art keywords
- bile acid
- signaling pathway
- long acting
- fgf21
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Abstract
La invención se refiere a un método de tratar un paciente que lo necesita con un agonista de acción prolongada a la vía de señalización FGF21. En una modalidad particular, la invención se refiere al uso de moléculas que estimulan la vía de señalización de FGF21, tales como polipéptidos de FGF21 de acción prolongada o anticuerpos agonistas, para tratar trastornos o enfermedades asociadas con el ácido biliar en exceso. La invención se refiere además a formulaciones farmacéuticas y dosificación de agonistas de acción prolongada de la vía de señalización de FGF21 adecuada para tratar trastornos relacionados con el ácido biliar.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562236050P | 2015-10-01 | 2015-10-01 | |
PCT/US2016/055017 WO2017059371A1 (en) | 2015-10-01 | 2016-09-30 | Treatment of bile acid disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018004041A true MX2018004041A (es) | 2018-11-09 |
Family
ID=57145043
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018004041A MX2018004041A (es) | 2015-10-01 | 2016-09-30 | Tratamiento de trastornos de acidos biliares. |
Country Status (8)
Country | Link |
---|---|
US (1) | US20180280474A1 (es) |
EP (1) | EP3355908A1 (es) |
JP (1) | JP2018529729A (es) |
AU (1) | AU2016332062A1 (es) |
CA (1) | CA3000697A1 (es) |
MA (1) | MA42985A (es) |
MX (1) | MX2018004041A (es) |
WO (1) | WO2017059371A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11679143B2 (en) | 2018-02-08 | 2023-06-20 | Sunshine Lake Pharma Co., Ltd. | FGF21 variant, fusion protein and application thereof |
US11427623B1 (en) | 2019-05-28 | 2022-08-30 | 89Bio Ltd. | Methods of treatment using mutant FGF-21 peptide conjugates |
WO2021139763A1 (zh) * | 2020-01-08 | 2021-07-15 | 上海翰森生物医药科技有限公司 | Fgf21突变体蛋白及其融合蛋白 |
CN113728013B (zh) | 2020-01-11 | 2022-06-14 | 北京质肽生物医药科技有限公司 | Glp-1和fgf21的融合蛋白的缀合物 |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
US4615885A (en) | 1983-11-01 | 1986-10-07 | Terumo Kabushiki Kaisha | Pharmaceutical composition containing urokinase |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
EP0315456B1 (en) | 1987-11-05 | 1994-06-01 | Hybritech Incorporated | Polysaccharide-modified immunoglobulins having reduced immunogenic potential or improved pharmacokinetics |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
EP0401384B1 (en) | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
WO1991010741A1 (en) | 1990-01-12 | 1991-07-25 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
US5470582A (en) | 1992-02-07 | 1995-11-28 | Syntex (U.S.A.) Inc. | Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles |
US5234784A (en) | 1992-04-01 | 1993-08-10 | Eastman Kodak Company | Method of making a projection viewable transparency comprising an electrostatographic toner image |
CA2140638C (en) | 1992-07-24 | 2010-05-04 | Raju Kucherlapati | Generation of xenogeneic antibodies |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
US6133426A (en) | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
US6342220B1 (en) | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
CN107188950B (zh) * | 2009-05-05 | 2021-09-28 | 安姆根有限公司 | Fgf21突变体及其用途 |
US20120052069A1 (en) * | 2009-05-05 | 2012-03-01 | Amgen Inc | Fgf21 mutants and uses thereof |
CA2845357A1 (en) * | 2011-08-31 | 2013-03-07 | Amgen Inc. | Method of treating or ameliorating type 1 diabetes using fgf21 |
CN105008548B (zh) * | 2012-12-27 | 2020-11-27 | 恩格姆生物制药公司 | 用于调节胆汁酸体内稳态以及治疗胆汁酸紊乱和疾病的方法 |
-
2016
- 2016-09-30 WO PCT/US2016/055017 patent/WO2017059371A1/en active Application Filing
- 2016-09-30 US US15/765,144 patent/US20180280474A1/en not_active Abandoned
- 2016-09-30 CA CA3000697A patent/CA3000697A1/en not_active Abandoned
- 2016-09-30 MA MA042985A patent/MA42985A/fr unknown
- 2016-09-30 AU AU2016332062A patent/AU2016332062A1/en not_active Abandoned
- 2016-09-30 JP JP2018516715A patent/JP2018529729A/ja active Pending
- 2016-09-30 MX MX2018004041A patent/MX2018004041A/es unknown
- 2016-09-30 EP EP16782352.5A patent/EP3355908A1/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
AU2016332062A1 (en) | 2018-04-26 |
WO2017059371A1 (en) | 2017-04-06 |
CA3000697A1 (en) | 2017-04-06 |
MA42985A (fr) | 2018-08-22 |
US20180280474A1 (en) | 2018-10-04 |
EP3355908A1 (en) | 2018-08-08 |
JP2018529729A (ja) | 2018-10-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018500586A1 (en) | Farnesoid x receptor agonists and uses thereof | |
PH12019502058A1 (en) | Farnesoid x receptor agonists and uses thereof | |
PH12020500286A1 (en) | Use of agonists of formly peptide receptor 2 for treating ocular inflammatory diseases | |
UY39119A (es) | Proteínas de fusión para tratar trastornos metabólicos | |
PH12018502538A1 (en) | Antibodies to alpha-synuclein and uses thereof | |
MX2018002990A (es) | Uso de la akkermansia pasteurizada para tratar trastornos metabolicos. | |
PH12016501809A1 (en) | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders | |
MX2019007834A (es) | Composiciones para modular la expresion de c9orf72. | |
EA201692109A1 (ru) | Варианты антител к фактору d и их применение | |
MX2017016134A (es) | Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad. | |
EA201790802A1 (ru) | Соединения против tnf | |
NZ751746A (en) | Combination therapy with controlled-release cnp agonists | |
PH12021550605A1 (en) | Farnesoid x receptor agonists and uses thereof | |
MX2018000352A (es) | 4-azaindoles sustituidos y su uso como moduladores del receptor glun2b. | |
MX2018004041A (es) | Tratamiento de trastornos de acidos biliares. | |
MA40364A (fr) | Polythérapie pour le traitement du cancer | |
MD20160007A2 (ro) | Inhibitori ai RORC2 şi metode de utilizare a acestora | |
MX2018015110A (es) | Arn modificado que codifica polipeptidos de vegf-a. formulaciones y usos relacionados con los mismos. | |
EA201691567A1 (ru) | Способы лечения легких травм головного мозга | |
EA201792571A1 (ru) | Терапевтическое применение l-4-хлорокинуренина | |
MX2017007054A (es) | Composiciones y métodos para usar solabegron de liberación modificada para sintomas del tracto urinario inferior. | |
MX2017009608A (es) | Compuestos anticancerigenos. | |
GB2537783A (en) | Methods and compositions used in treating inflammatory and autoimmune diseases | |
CR20210499A (es) | Compuestos y composiciones como moduladores de la señalización de tlr | |
PH12018500682A1 (en) | Oxa-diazaspiro compounds having activity against pain |